Patients in Australian Trials of Anavex 2-73 May Continue Using Therapy, Agency Says

Patients in Australian Trials of Anavex 2-73 May Continue Using Therapy, Agency Says
People in Australia with Alzheimer’s disease who have finished five years of treatment with Anavex 2-73 (blarcamesine) in Phase 2 clinical trials may continue to use Anavex Life Sciences' investigational oral therapy at their doctor's request. Under a special access scheme, the Therapeutic Goods Administration (TGA) — a part of the Australian Government Department of Health — allowed for compassionate use based on safety findings and early evidence of benefit in these clinical studies. A larger Phase 3 trial in early Alzheimer's patients is now underway and enrolling in Australia and parts of Europe. Canada is expected to open sites as well. Normally, therapies have to undergo thorough evaluations for efficacy, quality, and safety before they are made available. However, physicians may request to use medications that aren't approved but showing benefit to patients. "We are honored to support medical professionals and their patients seeking treatment for Alzheimer’s disease," Christopher Missling, PhD, the president and CEO of Anavex, said in a press relea
Subscribe or to access all post and page content.